Chieftek Precision Co Ltd
TWSE:1597
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Chieftek Precision Co Ltd
TWSE:1597
|
TW |
|
G
|
Globe Trade Centre SA
JSE:GTC
|
PL |
|
Kalvista Pharmaceuticals Inc
NASDAQ:KALV
|
US |
|
C
|
CULT Food Science Corp
CNSX:CULT
|
CA |
Balance Sheet
Balance Sheet Decomposition
Chieftek Precision Co Ltd
Chieftek Precision Co Ltd
Balance Sheet
Chieftek Precision Co Ltd
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
463
|
433
|
506
|
652
|
797
|
678
|
655
|
802
|
864
|
834
|
865
|
|
| Cash |
463
|
433
|
505
|
0
|
765
|
677
|
653
|
801
|
863
|
771
|
765
|
|
| Cash Equivalents |
0
|
0
|
1
|
652
|
32
|
1
|
1
|
1
|
1
|
63
|
100
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
8
|
7
|
7
|
8
|
24
|
111
|
|
| Total Receivables |
0
|
0
|
358
|
431
|
496
|
333
|
402
|
455
|
301
|
243
|
266
|
|
| Accounts Receivables |
0
|
0
|
324
|
400
|
432
|
299
|
345
|
401
|
282
|
225
|
230
|
|
| Other Receivables |
0
|
0
|
34
|
31
|
63
|
34
|
58
|
53
|
19
|
19
|
36
|
|
| Inventory |
0
|
0
|
319
|
374
|
684
|
637
|
557
|
442
|
636
|
647
|
641
|
|
| Other Current Assets |
0
|
0
|
17
|
23
|
22
|
29
|
36
|
109
|
125
|
66
|
35
|
|
| Total Current Assets |
0
|
0
|
1 199
|
1 480
|
1 998
|
1 684
|
1 657
|
1 814
|
1 933
|
1 815
|
1 917
|
|
| PP&E Net |
0
|
0
|
898
|
1 011
|
1 088
|
1 478
|
1 710
|
1 878
|
2 005
|
2 027
|
2 087
|
|
| PP&E Gross |
0
|
0
|
898
|
0
|
1 088
|
1 478
|
1 710
|
1 878
|
2 005
|
2 027
|
2 087
|
|
| Accumulated Depreciation |
615
|
740
|
856
|
0
|
1 011
|
1 091
|
1 160
|
1 224
|
1 293
|
1 330
|
1 393
|
|
| Intangible Assets |
0
|
0
|
69
|
123
|
125
|
121
|
102
|
80
|
71
|
63
|
55
|
|
| Long-Term Investments |
317
|
318
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
49
|
|
| Other Long-Term Assets |
0
|
0
|
29
|
24
|
36
|
37
|
40
|
25
|
45
|
50
|
52
|
|
| Total Assets |
0
N/A
|
0
N/A
|
2 196
N/A
|
2 639
+20%
|
3 247
+23%
|
3 320
+2%
|
3 509
+6%
|
3 797
+8%
|
4 054
+7%
|
3 955
-2%
|
4 160
+5%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
0
|
108
|
207
|
224
|
98
|
127
|
211
|
207
|
60
|
95
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
73
|
100
|
94
|
69
|
69
|
|
| Short-Term Debt |
0
|
0
|
188
|
215
|
210
|
313
|
379
|
230
|
225
|
365
|
160
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
59
|
70
|
57
|
106
|
100
|
84
|
146
|
85
|
300
|
|
| Other Current Liabilities |
0
|
0
|
85
|
172
|
283
|
160
|
46
|
123
|
160
|
73
|
54
|
|
| Total Current Liabilities |
0
|
0
|
440
|
664
|
774
|
677
|
726
|
747
|
832
|
652
|
678
|
|
| Long-Term Debt |
0
|
0
|
391
|
431
|
504
|
607
|
645
|
746
|
765
|
926
|
1 053
|
|
| Deferred Income Tax |
0
|
0
|
3
|
9
|
26
|
4
|
19
|
11
|
28
|
25
|
30
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
5
|
6
|
7
|
7
|
7
|
7
|
6
|
9
|
7
|
|
| Total Liabilities |
0
N/A
|
0
N/A
|
838
N/A
|
1 109
+32%
|
1 312
+18%
|
1 295
-1%
|
1 396
+8%
|
1 511
+8%
|
1 631
+8%
|
1 611
-1%
|
1 768
+10%
|
|
| Equity | ||||||||||||
| Common Stock |
0
|
0
|
620
|
620
|
738
|
812
|
812
|
812
|
893
|
893
|
893
|
|
| Retained Earnings |
0
|
0
|
399
|
577
|
774
|
802
|
923
|
1 111
|
1 257
|
1 177
|
1 203
|
|
| Additional Paid In Capital |
0
|
0
|
463
|
463
|
441
|
441
|
441
|
441
|
446
|
446
|
446
|
|
| Treasury Stock |
113
|
119
|
119
|
119
|
0
|
0
|
27
|
27
|
148
|
148
|
148
|
|
| Other Equity |
0
|
0
|
6
|
12
|
17
|
29
|
36
|
51
|
24
|
25
|
2
|
|
| Total Equity |
0
N/A
|
0
N/A
|
1 358
N/A
|
1 530
+13%
|
1 936
+27%
|
2 025
+5%
|
2 113
+4%
|
2 286
+8%
|
2 423
+6%
|
2 344
-3%
|
2 392
+2%
|
|
| Total Liabilities & Equity |
0
N/A
|
0
N/A
|
2 196
N/A
|
2 639
+20%
|
3 247
+23%
|
3 320
+2%
|
3 509
+6%
|
3 797
+8%
|
4 054
+7%
|
3 955
-2%
|
4 160
+5%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
0
|
89
|
89
|
89
|
89
|
89
|
89
|
87
|
87
|
87
|
|